This treatment method works by inhibiting hypoxia-induced YAP nuclear translocation, leading to a reduction in the transcription of downstream target genes, such as VEGF-A and Ang-2. This ultimately results in anti-angiogenic activity, which helps in preventing and treating hepatic fibrosis. The gene discussed is VEGFA; the disease is Hepatic fibrosis.